DCP2 and ovarian cancer: We scored the primary and metastatic foci separately in tissue microarrays and analyzed the relationship between these two genes and metastases at the clinical sample level with positive statistical results (Figures 8F, G).The k-m curves obtained from the analysis of immunohistochemical staining of tissue microarrays and clinical prognostic information showed that high expression of DCP2 was associated with poor prognosis, while high expression of NUDT16 improved the survival of ovarian cancer patients(Figures 8H, I).